Potential Role of Bone Metabolism Markers in Kidney Transplant Recipients
- Authors: Vigil F.1, Castro P.2, Hasparyk U.3, Bartolomei V.3, Silva A.4
-
Affiliations:
- Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG),
- Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG
- Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG)
- nterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG)
- Issue: Vol 31, No 19 (2024)
- Pages: 2809-2820
- Section: Anti-Infectives and Infectious Diseases
- URL: https://jdigitaldiagnostics.com/0929-8673/article/view/644597
- DOI: https://doi.org/10.2174/0109298673250291231121052433
- ID: 644597
Cite item
Full Text
Abstract
Background:The impact of treatments, suppressing the immune system, persistent hyperparathyroidism, and other risk factors on mineral and bone disorder (MBD) after kidney transplantation is well-known. However, there is limited knowledge about their effect on bone metabolism biomarkers. This study aimed to investigate the influence of kidney transplant on these markers, comparing them to patients undergoing hemodialysis and healthy individuals.
Methods:In this cross-sectional study, three groups were included: kidney transplant patients (n = 57), hemodialysis patients (n = 26), and healthy controls (n = 31). Plasma concentrations of various bone metabolism biomarkers, including Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, sclerostin, and fibroblast growth factor 23, were measured. Associations between these biomarkers and clinical and laboratory data were evaluated.
Results:A total of 114 patients participated. Transplant recipients had significantly lower levels of Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, sclerostin, and fibroblast growth factor 23 compared to hemodialysis patients. Alkaline phosphatase levels positively correlated with osteopontin (r = 0.572, p < 0.001), while fibroblast growth factor 23 negatively correlated with 25-hydroxyvitamin D (r = -0.531, p = 0.019). The panel of bone biomarkers successfully predicted hypercalcemia (area under the curve [AUC] = 0.852, 95% confidence interval [CI] = 0.679-1.000) and dyslipidemia (AUC = 0.811, 95% CI 0.640-0.982) in transplant recipients.
Conclusion:Kidney transplantation significantly improves mineral and bone disorders associated with end-stage kidney disease by modulating MBD markers and reducing bone metabolism markers, such as Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, and sclerostin. Moreover, the panel of bone biomarkers effectively predicted hypercalcemia and dyslipidemia in transplant recipients.
About the authors
Flávia Vigil
Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG),
Email: info@benthamscience.net
Pedro Castro
Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG
Email: info@benthamscience.net
Ursula Hasparyk
Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG)
Email: info@benthamscience.net
Victória Bartolomei
Interdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG)
Email: info@benthamscience.net
Ana Silva
nterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine,, Federal University of Minas Gerais (UFMG)
Author for correspondence.
Email: info@benthamscience.net
References
- Kidney disease: Improving global outcomes (KDIGO) CKD-MBD update work group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl., 2011, 2017(7), 1-59.
- Bouquegneau, A.; Salam, S.; Delanaye, P.; Eastell, R.; Khwaja, A. Bone disease after kidney transplantation. Clin. J. Am. Soc. Nephrol., 2016, 11(7), 1282-1296. doi: 10.2215/CJN.11371015 PMID: 26912549
- Moe, S.M.; Chen, N.X. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol., 2008, 19(2), 213-216. doi: 10.1681/ASN.2007080854 PMID: 18094365
- Mazzaferro, S.; Pasquali, M.; Taggi, F.; Baldinelli, M.; Conte, C.; Muci, M.L.; Pirozzi, N.; Carbone, I.; Francone, M.; Pugliese, F. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin. J. Am. Soc. Nephrol., 2009, 4(3), 685-690. doi: 10.2215/CJN.03930808 PMID: 19211668
- Mazzaferro, S.; Pasquali, M.; Pugliese, F.; Barresi, G.; Carbone, I.; Francone, M.; Sardella, D.; Taggi, F. Serum levels of calcification inhibition proteins and coronary artery calcium score: Comparison between transplantation and dialysis. Am. J. Nephrol., 2007, 27(1), 75-83. doi: 10.1159/000099095 PMID: 17259697
- Elias, R.M.; Moysés, R.M.A. Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism. Int. Urol. Nephrol., 2017, 49(10), 1815-1821. doi: 10.1007/s11255-017-1650-7 PMID: 28695313
- Evenepoel, P.; Claes, K.; Kuypers, D.; Maes, B.; Bammens, B.; Vanrenterghem, Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol. Dial. Transplant., 2004, 19(5), 1281-1287. doi: 10.1093/ndt/gfh128 PMID: 14993493
- Reinhardt, W.; Bartelworth, H.; JockenhA vel, F.; Schmidt-Gayk, H.; Witzke, O.; Wagner, K.; Heemann, U.W.; Reinwein, D.; Philipp, T.; Mann, K. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol. Dial. Transplant., 1998, 13(2), 436-442. doi: 10.1093/oxfordjournals.ndt.a027843 PMID: 9509459
- Julian, B.A.; Laskow, D.A.; Dubovsky, J.; Dubovsky, E.V.; Curtis, J.J.; Quarles, L.D. Rapid loss of vertebral mineral density after renal transplantation. N. Engl. J. Med., 1991, 325(8), 544-550. doi: 10.1056/NEJM199108223250804 PMID: 1857390
- Cejka, D.; Jäger-Lansky, A.; Kieweg, H.; Weber, M.; Bieglmayer, C.; Haider, D.G.; Diarra, D.; Patsch, J.M.; Kainberger, F.; Bohle, B.; Haas, M. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol. Dial. Transplant., 2012, 27(1), 226-230. doi: 10.1093/ndt/gfr270 PMID: 21613383
- Cejka, D.; Herberth, J.; Branscum, A.J.; Fardo, D.W.; Monier-Faugere, M.C.; Diarra, D.; Haas, M.; Malluche, H.H. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol., 2011, 6(4), 877-882. doi: 10.2215/CJN.06550810 PMID: 21164019
- Cianciolo, G.; Capelli, I.; Angelini, M.L.; Valentini, C.; Baraldi, O.; Scolari, M.P.; Stefoni, S. Importance of vascular calcification in kidney transplant recipients. Am. J. Nephrol., 2014, 39(5), 418-426. doi: 10.1159/000362492 PMID: 24819032
- Si, J.; Wang, C.; Zhang, D.; Wang, B.; Hou, W.; Zhou, Y. Osteopontin in bone metabolism and bone diseases. Med. Sci. Monit., 2020, 26, e919159. doi: 10.12659/MSM.919159 PMID: 31996665
- Wada, T.; McKee, M.D.; Steitz, S.; Giachelli, C.M. Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ. Res., 1999, 84(2), 166-178. doi: 10.1161/01.RES.84.2.166 PMID: 9933248
- Rao, M.; Jain, P.; Ojo, T.; Surya, G.; Balakrishnan, V. Fibroblast growth factor and mineral metabolism parameters among prevalent kidney transplant patients. Int. J. Nephrol., 2012, 2012, 1-6. doi: 10.1155/2012/490623 PMID: 22811905
- Strengthening the reporting of observational studies in epidemiology. Available from: https://www.strobe-statement.org/checklists/
- Metz, C.E. Basic principles of ROC analysis. Semin. Nucl. Med., 1978, 8(4), 283-298. doi: 10.1016/S0001-2998(78)80014-2 PMID: 112681
- Economidou, D.; Dovas, S.; Papagianni, A.; Pateinakis, P.; Memmos, D. FGF-23 levels before and after renal transplantation. J. Transplant., 2009, 2009, 1-5. doi: 10.1155/2009/379082 PMID: 20107581
- Araújo, S.A.; Cordeiro, T.M.; Belisário, A.R.; Araújo, R.F.A.; Marinho, P.E.S.; Kroon, E.G.; de Oliveira, D.B.; Teixeira, M.M.; Simões e Silva, A.C. First report of collapsing variant of focal segmental glomerulosclerosis triggered by arbovirus: Dengue and Zika virus infection. Clin. Kidney J., 2019, 12(3), 355-361. doi: 10.1093/ckj/sfy104 PMID: 31198534
- Bonani, M.; Rodriguez, D.; Fehr, T.; Mohebbi, N.; Brockmann, J.; Blum, M.; Graf, N.; Frey, D.; Wüthrich, R.P. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press. Res., 2014, 39(4), 230-239. doi: 10.1159/000355781 PMID: 25118597
- van Lierop, A.H.; van der Eerden, A.W.; Hamdy, N.A.T.; Hermus, A.R.; den Heijer, M.; Papapoulos, S.E. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J. Clin. Endocrinol. Metab., 2012, 97(10), E1953-E1957. doi: 10.1210/jc.2012-2218 PMID: 22844062
- Cejka, D.; Marculescu, R.; Kozakowski, N.; Plischke, M.; Reiter, T.; Gessl, A.; Haas, M. Renal elimination of sclerostin increases with declining kidney function. J. Clin. Endocrinol. Metab., 2014, 99(1), 248-255. doi: 10.1210/jc.2013-2786 PMID: 24187403
- Tartaglione, L.; Pasquali, M.; Rotondi, S.; Muci, M.L.; Leonangeli, C.; Farcomeni, A.; Fassino, V.; Mazzaferro, S. Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS One, 2017, 12(5), e0178637. doi: 10.1371/journal.pone.0178637 PMID: 28558021
- Schlieper, G.; Schurgers, L.; Brandenburg, V.; Reutelingsperger, C.; Floege, J. Vascular calcification in chronic kidney disease: An update. Nephrol. Dial. Transplant., 2016, 31(1), 31-39. doi: 10.1093/ndt/gfv111 PMID: 25916871
- Oschatz, E.; Benesch, T.; Kodras, K.; Hoffmann, U.; Haas, M. Changes of coronary calcification after kidney transplantation. Am. J. Kidney Dis., 2006, 48(2), 307-313. doi: 10.1053/j.ajkd.2006.04.066 PMID: 16860198
- Malluche, H.H.; Monier-Faugere, M.C.; Herberth, J. Bone disease after renal transplantation. Nat. Rev. Nephrol., 2010, 6(1), 32-40. doi: 10.1038/nrneph.2009.192 PMID: 19918255
- Morena, M.; Jaussent, I.; Dupuy, A.M.; Bargnoux, A.S.; Kuster, N.; Chenine, L.; Leray-Moragues, H.; Klouche, K.; Vernhet, H.; Canaud, B.; Cristol, J.P. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: Potential partners in vascular calcifications. Nephrol. Dial. Transplant., 2015, 30(8), 1345-1356. doi: 10.1093/ndt/gfv081 PMID: 25854266
- Vangala, C.; Pan, J.; Cotton, R.T.; Ramanathan, V. Mineral and bone disorders after kidney transplantation. Front. Med., 2018, 5, 211. doi: 10.3389/fmed.2018.00211 PMID: 30109232
- Magalhães, J.; Quelhas-Santos, J.; Pereira, L.; Neto, R.; Castro-Ferreira, I.; Martins, S.; Frazão, J.M.; Carvalho, C. Could bone biomarkers predict bone turnover after kidney transplantation?a proof-of-concept study. J. Clin. Med., 2022, 11(2), 457. doi: 10.3390/jcm11020457 PMID: 35054152
- Trueba, D.; Sawaya, B.P.; Mawad, H.; Malluche, H.H. Bone biopsy: Indications, techniques, and complications. Semin. Dial., 2003, 16(4), 341-345. doi: 10.1046/j.1525-139X.2003.160631.x PMID: 12926408
- Seoane-Pillado, M.T.; Pita-Fernández, S.; Valdés-Cañedo, F.; Seijo-Bestilleiro, R.; Pértega-Díaz, S.; Fernández-Rivera, C.; Alonso-Hernández, Á.; González-Martín, C.; Balboa-Barreiro, V. Incidence of cardiovascular events and associated risk factors in kidney transplant patients: A competing risks survival analysis. BMC Cardiovasc. Disord., 2017, 17(1), 72. doi: 10.1186/s12872-017-0505-6 PMID: 28270107
- Mikolasevic, I.; utelija, M.; Mavrinac, V.; Orlic, L. Dyslipidemia in patients with chronic kidney disease: Etiology and management. Int. J. Nephrol. Renovasc. Dis., 2017, 10, 35-45. doi: 10.2147/IJNRD.S101808 PMID: 28223836
- Maria Borges Vigil, F.; Alves Soares Vaz de Castro, P.; Gramiscelli Hasparyk, Ú.; Soares Bartolomei, V.; Cristina Simões e Silva, A. MO947: Evaluation of bone metabolism markers in kidney transplant recipients. Nephrology Dialysis Transplantation, 2022, 37, 1685-1686.
Supplementary files
